In today’s Pharmaceutical Executive Daily, GSK moves to strengthen its immunology pipeline with a $2 billion acquisition of ...

In today's healthcare environment, securing regulatory approval is only the beginning. The real challenge lies in ensuring ...

GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...

A new study suggests that there is no link between Tylenol and autism. More specifically, the research shows that women ...

The alternative is to purchase a fit-for-purpose solution. This approach requires in-depth investigation to ensure that the ...

As a result of the acquisition, Pfizer will no longer hold shares of ViiV Healthcare Limited and Shionogi will see its holdings increase to 21.7%. 1 The majority shareholder of ViiV Healthcare Limited ...

Despite pledges to lower drug costs through Trump-backed pricing deals and direct-to-patient programs, pharmaceutical ...

Ahead of her presentation at JP Morgan, Pharmaceutical Technology spoke with Dr. Jennifer Levin Carter, MD, founder and CEO ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

Atkins is leveraging a partnership with reality TV star Heather Gay and early clinical trial data to reposition nutrition as ...

Shanghai Henlius Biotech, Inc. announced that it entered into an exclusive global license agreement with U-mab Biopharma ...

Jeff Liter, CEO of Luminary Therapeutics, discusses the importance of demonstrating clinical evidence at the JP Morgan ...